Okay, let's tackle this question. The question is about the indication of methotrexate in molar pregnancy. First, I need to remember what a molar pregnancy is. It's a type of gestational trophoblastic disease where abnormal placental tissue grows instead of a normal embryo. There are two types: complete and partial hydatidiform moles.

Now, methotrexate is an antimetabolite, which is an antifolate drug. It inhibits dihydrofolate reductase, which is needed for DNA synthesis. But how does that relate to molar pregnancy? I recall that molar pregnancies can lead to persistent trophoblastic disease, which is when the abnormal tissue doesn't go away after treatment. In some cases, chemotherapy is needed. Methotrexate is often used for low-risk cases of gestational trophoblastic neoplasia (GTN), which can follow a molar pregnancy.

Wait, so the indication for methotrexate in this context would be to treat persistent or invasive GTN. But maybe it's also used for the initial management? No, the initial treatment for molar pregnancy is usually suction evacuation. Methotrexate comes into play if there's persistent disease with elevated hCG levels. So the correct answer would be when there's evidence of persistent trophoblastic disease after evacuation.

Looking at the options, even though they aren't provided, the correct answer should be related to treating persistent disease. The other options might include things like preventing molar pregnancy (which isn't the case), treating normal pregnancy, or using in early stages where it's not indicated. For example, options might suggest using methotrexate for all molar pregnancies, which is incorrect because only a subset requires chemotherapy.

Clinical pearls: Methotrexate is a first-line agent for low-risk GTN. It's important to monitor hCG levels post-evacuation to detect persistent disease. Also, high-risk cases might require more aggressive treatment like actinomycin D or combination therapy.

So the explanation should cover the core concept of using methotrexate for persistent GTN after molar pregnancy, explain why other options are wrong (like using it prophylactically or for non-chemotherapy indications), and highlight the high-yield fact about monitoring hCG and treatment selection based on risk factors.

**Core Concept**
Methotrexate is an antimetabolite used in **gestational trophoblastic neoplasia (GTN)**, a complication of molar pregnancies. It inhibits dihydrofolate reductase, impairing DNA synthesis in rapidly dividing trophoblastic cells. Its indication is based on **persistent or invasive disease** after evacuation, not prophylaxis.

**Why the Correct Answer is Right**
Methotrexate is indicated for **low-risk GTN** following molar pregnancy when serial β-hCG levels fail to normalize, indicating residual trophoblastic tissue. It is not used for all molar pregnancies but specifically for patients with histologically confirmed GTN, elevated hCG post-evacuation, or features like theca lutein cysts. The drug’s efficacy in this context is due to its ability to target trophoblastic proliferation and prevent metastasis.

**Why Each Wrong Option is Incorrect**
**Option A:** Suggests methotrexate

✓ Correct Answer: D. Evidence of metastasis